Resonance Health Ltd’s (ASX: RHT) flagship FerriScan product is now available for use on tesla 3T MRI scanning machines.
FerriScan is internationally recognised by clinicians as the gold standard for the measurement of liver iron concentration (LIC) for patients suffering iron overload disorders.
This accurate MRI-based technique is non-invasive and eliminates the need for liver biopsies. FerriScan is recommended in multiple clinical patient management guidelines and international standards of care.
Since the company’s inception, Resonance Health has completed over 58,000 FerriScan analyses to assist patients suffering iron overload disorders around the world. Until now, the FerriScan service has only been available at MRI facilities with 1.5 tesla (1.5T) field strength MRI machines.
The company commenced studies aiming to adapt the FerriScan acquisition protocol from 1.5T to 3T MRI scanners, which would allow for better usability of the FerriScan service across a broader range of MRI machines.
Resonance has now successfully finalised the calibration of the FerriScan protocol, with the product now commercially available for use in clinical trials and in the routine clinical management of patients, on both 1.5T and 3T MRI machines.
3T MRI machines offer advantages for clinicians and patients, including shorter scan times and greater image contrast compared with 1.5T MRI machines, and are growing in prevalence around the world. In the United States, 1.5T and 3T scanners are now being purchased in approximately equal numbers and dominate new sales, with 3T scanners already representing approx. 15% to 18% of total MRI scanners in Europe and North America.
Work also to progress for the adaptation of FerriSmart, the company’s Artificial Intelligence (AI) evolution of FerriScan, to 3T MRI scanning machines. This will further enhance availability and convenience for clinicians and patients in large new markets.
